← All trials
NCT05270044
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2022
- Primary completion
- Mar 31, 2027
- Completion date
- May 2, 2035
- First posted
- Mar 8, 2022
- Last posted
- Dec 7, 2022
- Enrollment
- 815
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pierre FabreLead sponsor
- European Organisation for Research and Treatment of CancerCollaborator
- European Organisation for Research and Treatment of CancerStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.